Welcome to our dedicated page for NYMX news (Ticker: NYMX), a resource for investors and traders seeking the latest updates and insights on NYMX stock.
Nymox Pharmaceutical Corporation (symbol: NYMX) is a biopharmaceutical company dedicated to the research and development of innovative drugs targeting the aging population. Founded in 1989 and headquartered in Nassau, Bahamas, Nymox operates internationally, including in Canada, the United States, and Europe.
The company's lead drug candidate, Fexapotide Triflutate (NX-1207), is designed to treat benign prostatic hyperplasia (BPH). Having successfully completed Phase III clinical trials, NX-1207 is now in Phase II trials for treating low-grade localized prostate cancer and is also undergoing preclinical studies for hepatocellular carcinoma.
Nymox offers several diagnostic products, such as Nicalert and TobacAlert test strips, which use urine or saliva to detect nicotine and tobacco product use. Another significant product is Alzheimalert, a proprietary urine assay that helps physicians diagnose Alzheimer's disease.
Recently, Nymox made headlines with the issuance of several important U.S. patents for NYMOZARFEX, showcasing significant progress in their research efforts. The latest studies indicate that a minimal treatment of 15 mg NYMOZARFEX leads to a significant long-term reduction in prostate cancer surgeries and radiotherapies for patients with low-grade prostate cancer.
With a commitment to advancing healthcare solutions for an aging demographic, Nymox Pharmaceutical Corporation continues to be at the forefront of biopharmaceutical innovation, making impactful strides in the detection and treatment of age-related diseases.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced the submission of its New Drug Application (NDA) to the FDA for Fexapotide Triflutate, aimed at treating benign prostatic hyperplasia (BPH). This marks a significant step towards potential marketing approval in the U.S. However, the company highlighted that there are no guarantees regarding the submission outcomes. Nymox plans to submit applications in other major markets shortly and will continue to update stakeholders on the application process and related developments.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) has completed essential preparations for its upcoming regulatory submission for Fexapotide Triflutate, aimed at treating Benign Prostatic Hyperplasia (BPH). CEO Paul Averback expressed satisfaction with overcoming recent delays and noted that the submission application timeline will be communicated promptly. Clinical trials revealed Fexapotide's significant benefits, including low prostate cancer incidence and acute urinary retention rates, suggesting a promising treatment alternative for patients intolerant of standard medications.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced its participation in the Torrey Hills Capital Emerging Growth Conference in San Diego this week. The company expressed enthusiasm for networking with high-caliber investors and plans to make additional presentations to the investment community. Nymox specializes in developing therapeutics targeting unmet needs of the aging male population, particularly its lead drug candidate, Fexapotide Triflutate (FT), which has completed Phase 3 trials involving over 1,700 patients and is preparing for approval applications in the U.S. and Europe.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced a positive update on the progress of its Fexapotide filing, confirming that key vendor documentation has been completed. CEO Paul Averback highlighted that standard quality control steps are underway, with a future update anticipated soon. The company also plans to participate in investor conferences in the upcoming months. Fexapotide Triflutate, the lead candidate for benign prostatic hyperplasia, has completed Phase 3 trials across over 70 clinical centers and is preparing for global regulatory submissions.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced progress on its BPH treatment product, Fexapotide Triflutate. The company has completed all tasks for the upcoming filing process, with only minor delays due to third-party documentation. Nymox has received regulatory acceptance for proposed brand names and is set to file for patents in several jurisdictions, enhancing its intellectual property protection. CEO Dr. Paul Averback expressed confidence in the company’s progress, indicating that the filing will happen soon with updates promised within 30 days.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is set to file for marketing approval of Fexapotide Triflutate for benign prostatic hyperplasia (BPH) by September 15, 2021. CEO Dr. Paul Averback expressed hopes for an earlier filing. The clinical development of Fexapotide involved over 1,700 patients across more than 70 centers in the U.S. This move is crucial for addressing unmet needs in the aging male population. However, the company acknowledges the inherent risks and uncertainties in the drug approval process.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced a private placement of 3,669,724 shares of common stock and warrants for 1,834,862 shares at a price of $2.18, totaling approximately $8 million before expenses. The warrants have an exercise price of $2.50 and are valid for five years. Proceeds will be used for working capital and corporate purposes. The transaction is expected to close by April 30, 2021, subject to customary conditions. Nymox is focused on developing treatments for benign prostatic hyperplasia with its lead candidate, Fexapotide Triflutate.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced its plans to file for regulatory approval of Fexapotide Triflutate, a novel treatment for BPH, by summer 2021. The exact filing date will be shared within six weeks. CEO Paul Averback expressed confidence in their timeline and the product's potential to improve men's health significantly. He highlighted that current BPH treatments have not changed in over 30 years, marking this as a crucial development. The company is committed to transparency and will update on any delays.
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced significant progress in the regulatory filing of Fexapotide Triflutate (FT) for benign prostatic hyperplasia (BPH). Delays were primarily due to extensive data requirements and Covid-related inefficiencies. The company is confident that filings will be completed in Q1 2021. Management invested USD $510,000 in the company's shares recently. Additionally, nine new international patents for FT have been issued, enhancing product coverage. FT shows promise for treating BPH and early prostate cancer with long-term efficacy and fewer side effects.
FAQ
What is the market cap of NYMX (NYMX)?
What is Nymox Pharmaceutical Corporation's main area of research?
What is Fexapotide Triflutate (NX-1207)?
What are some of the diagnostic products developed by Nymox?
Where is Nymox Pharmaceutical Corporation headquartered?
What recent achievements has Nymox announced?
Which markets does Nymox Pharmaceutical Corporation operate in?
How does Nicalert and TobacAlert work?
What phase is NX-1207 in for treating low-grade localized prostate cancer?
What is Alzheimalert?
When was Nymox Pharmaceutical Corporation founded?
